This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Parnaparin is a low molecular weight heparin (LMWH) used to prevent blood clots, specifically deep vein thrombosis.

Generic Name
Parnaparin
DrugBank Accession Number
DB09260
Background

Parnaparin is an heparin of low molecular weight with antithrombotic effects.

Type
Small Molecule
Groups
Approved, Investigational
Synonyms
  • Parnaparin sodium

Pharmacology

Indication

Used in the prevention and treatment of venous thromboembolism (deep vein thrombosis and pulmonary embolism) and in the treatment of myocardial infarction.

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of bleeding can be increased when Abciximab is combined with Parnaparin.
AcebutololThe risk or severity of hyperkalemia can be increased when Acebutolol is combined with Parnaparin.
AceclofenacThe risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Parnaparin.
AcemetacinThe risk or severity of bleeding and hemorrhage can be increased when Parnaparin is combined with Acemetacin.
AcenocoumarolThe risk or severity of bleeding can be increased when Acenocoumarol is combined with Parnaparin.
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Parnaparin.
Albutrepenonacog alfaThe therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Parnaparin.
AlclofenacThe risk or severity of bleeding and hemorrhage can be increased when Alclofenac is combined with Parnaparin.
AldesleukinThe risk or severity of bleeding can be increased when Parnaparin is combined with Aldesleukin.
AlemtuzumabThe risk or severity of bleeding can be increased when Parnaparin is combined with Alemtuzumab.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
  • Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now

Categories

ATC Codes
B01AB07 — Parnaparin
Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
U6K360XMIU
CAS number
9005-49-6
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

References

General References
  1. Maugeri N, Di Fabio G, Barbanti M, de Gaetano G, Donati MB, Cerletti C: Parnaparin, a low-molecular-weight heparin, prevents P-selectin-dependent formation of platelet-leukocyte aggregates in human whole blood. Thromb Haemost. 2007 Jun;97(6):965-73. [Article]
PubChem Substance
347910424
RxNav
69528
Wikipedia
Parnaparin_sodium

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentThrombophlebitis1
3TerminatedTreatmentInfertility / Low Molecular Weight Heparin1
3TerminatedTreatmentRetinal Vein Occlusion1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
InjectionSubcutaneous
Injection, solutionSubcutaneous12800 IU/ml
Injection, solutionSubcutaneous3200 IU/0.3ml
Injection, solutionSubcutaneous4250 IU/0.4ml
Injection, solutionSubcutaneous6400 IU/0.6ml
Injection, solutionSubcutaneous8500 IU/0.8ml
Injection, solutionSubcutaneous
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at October 26, 2015 17:08 / Updated at May 05, 2021 20:31